JAKARTA, Aug 6, 2025 - (ACN Newswire via SeaPRwire.com) - Chinese automotive company SERES and electric vehicle brand AITO launched a road tour from Chongqing to Jakarta on Monday (4/8) to test the brand's durability, as well as celebrate 75 years of Indonesia-China diplomatic relations. The "Open the Way with AITO" road tour will pass through several ASEAN countries on its way to Jakarta, covering a route of 5,000 kilometers. Vehicles on the tour are the AITO M5, AITO M7, and AITO M9.Indonesian Chamber of Commerce and Industry China Committee (KIKT) Chairman Garibaldi 'Boy' Thohir, SERES Automobile President Leon He, and Indonesian Ambassador to China and Mongolia Djauhari Oratmangun at Chongqing-Jakarta AITO Road Tour launch in Chongqing, China on Aug 4."The KIKT (Indonesian Chamber of Commerce and Industry Bilateral Committee for China) is here in Chongqing to launch this major event where AITO vehicles will travel a route from Chongqing, China to Indonesia, with a big welcoming event planned on August 25 in Jakarta," said KIKT Chairman Garibaldi "Boy" Thohir to ANTARA after the launch event in Chongqing on Monday.The road tour, titled "Open the Way with AITO," will pass through several ASEAN countries on its way to Jakarta, covering a route of about 5,000 kilometers. The AITO vehicles in the road tour are the AITO M5, AITO M7, and AITO M9."The Chinese government, especially President Xi Jinping, has promoted 'One Belt One Road,' and this is one example of the Silk Road from Chongqing to Indonesia. With this event, we also hope to attract the attention of young people," Boy added.Young people will be represented in the event by celebrities such as Boy William and Gading Marten, as well as Kanjeng Gusti Pangeran Adipati Arya (KGPAA) Mangkunegara X Bhre Cakrahutomo Wira Sudjiwo, commonly known as Gusti Bhre."Because many young people like fun, informal things, I am involving Boy William and Gading Marten to be icons so that young Indonesians can see how far Chinese technology has progressed, and especially the good relationship between the two countries," Boy explained.The Indonesian Ambassador to China and Mongolia, Djauhari Oratmangun, stated that this event was not only related to Indonesia and China but to several ASEAN countries. "This shows that the NEV (new energy vehicle) industry will enter Indonesia and produce in Indonesia for the ASEAN market, and therefore the Indonesian Embassy in Beijing fully supports it," said Ambassador Djauhari. Ambassador Djauhari sees renewable energy vehicles (New Energy Vehicles) as part of the green economy. "We have the materials, especially for producing batteries as the main component of the electric vehicle industry. Therefore, we welcome the presence of the electric vehicle industry in Indonesia, and China has become one of the world's main producers of electric vehicles," Ambassador Djauhari added.In his remarks, Ambassador Djauhari said that young people, innovators, and even tourists are beginning to play a role in Indonesia-China relations. "Events like this spark a curiosity, a spirit of adventure and mutual understanding. As this tour starts from Chongqing, the hope is that it can also bring about a more integrated ASEAN-China region, a more strategic, sustainable, and comprehensive Indonesia-China partnership, and a stronger, more environmentally friendly future," Ambassador Djauhari explained.SERES Automotive President Leon He said that AITO had previously undertaken a similar overland expedition in Europe. "Last year's expedition covered 15,000 km in 38 days to Paris, which proved the toughness of our vehicles. This year, the journey will continue to Indonesia, a strategic market with an economic potential of 150 billion US dollars and a strong commitment to new energy vehicles," said Leon He.Leon He noted that the presence of the SERES factory in Sokonindo, Indonesia since 2017 has been an important stepping stone for expansion in the ASEAN region. The AITO brand itself has not yet entered Indonesia, but SERES Automobile has been present through PT Sokonindo Automobile, which oversees the DFSK brand.The Sokonindo factory has stood since 2017 in the Modern Cikande Industrial Estate, Serang, Banten, covering 20 hectares, with a total investment of USD 150 million and a maximum production capacity of 50,000 units per year for both domestic and international markets. Indonesian Chamber of Commerce and Industry: https://kadin.id/en/ Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 5, 2025 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) today announced that the supplemental application for the production expansion of NEFECON® has been officially approved by China’s National Medical Products Administration (NMPA). This approval for production expansion will further boost capacity and increase product supply, enabling a more efficient response to the growing clinical demand in China and across Asia.NEFECON® is the first and only etiological treatment for IgA nephropathy (IgAN) to receive full approval in China, the United States, and Europe, serving as a foundational first-line therapy for patients with IgAN. Since its initial approval in China in November 2023, NEFECON® was subsequently included in the National Reimbursement Drug List (NRDL) in November 2024, and received full approval from the NMPA in May 2025, irrespective of proteinuria levels, benefiting most individuals living with IgAN.NEFECON® specifically modulates the mucosal immune system in the gut to reduce the formation of pathogenic galactose-deficient IgA1 (Gd-IgA1) that trigger IgAN. Results from the Phase 3 clinical study NefIgArd demonstrated that NEFECON® reduces the decline in kidney function by 50%. Results from Phase 3 clinical study NefIgArd of the Chinese population shows that NEFECON® reduces kidney function decline by 66%, and delays disease progression to dialysis or kidney transplantation by 12.8 years.“The expansion of our NEFECON® production capacity will help better meet the growing clinical treatment needs of IgAN patients in China.” Said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “China has one of the highest rates of primary glomerular disease in the world, with more than 5 million patients estimated to be living with IgAN and over 100,000 new cases diagnosed each year. Chinese IgAN patients generally experience faster disease progression and poorer prognosis, highlighting a significant unmet medical need.As the only etiological treatment for IgAN currently recommended by both international and Chinese guidelines, the expansion of NEFECON® production will further accelerate the uptake of etiological treatment, enabling more patients to access standardized treatment earlier to delay disease progression and protect kidney function. We will continue to enhance the accessibility and affordability of NEFECON®, supporting its advancement from ‘changing the treatment landscape’ to ‘redefining the standard of care’.”NEFECON®, as the only in-disease IgAN treatment has been included in the KDIGO 2024 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) (public review draft), making it the only targeted therapy endorsed by both international and Chinese guidelines. NEFECON® has been approved across all Everest Medicines’ territories, including mainland China, Hong Kong SAR, Macau SAR, Taiwan region, China, as well as Singapore and South Korea, and continues to expand its therapeutic impact across Asia.As production capacity continues to grow and supply capabilities improve, NEFECON® is well positioned to benefit a broader patient population by accelerating the uptake of etiological treatment, enabling more patients to access standardized care earlier to delay disease progression and preserve kidney function. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 5, 2025 - (ACN Newswire via SeaPRwire.com) - On August 4, the China Robotics Industry ETF (159551) rose by 2.44%, as investor enthusiasm for the sector continues to surge. Humanoid robotics is transitioning from a phase of “technical breakthroughs” to one of “scenario implementation,” marking the start of a new acceleration cycle. With a series of industry catalysts unfolding, the robotics segment in the Hong Kong market is entering a structural upswing.Among the emerging opportunities, Shoucheng Holdings (0697.HK) stands out as a rare asset platform company with full-chain industrial deployment and real scenario execution capability.1. From Showroom to Deployment: Humanoid Robots Hit the Ground RunningAt the 2025 World Artificial Intelligence Conference (WAIC) held in late July, over 150 humanoid robots were demonstrated performing real-time dynamic tasks across industrial, service, and medical settings — a first in China. Unlike previous static displays, this year’s event showcased robots in real application scenarios such as cleaning, concierge services, and logistics handling, demonstrating the rapid convergence of hardware, algorithms, and computing power.At the same time, major news continues to drive investor sentiment:Unitree Robotics has entered IPO counseling, and the World Robot Conference 2025 is set to launch with over 100 new product debuts.In this context, Shoucheng Holdings stands out as a rare Hong Kong-listed company with both industrial integration capabilities and operational execution power, filling a critical gap in the market.2. From Conference to Application: Shoucheng’s Robot Ecosystem Comes AliveWhile many firms are still stuck in the “capital narrative” stage, Shoucheng Holdings is entering a phase of real industrial depth, evolving from investor to industrial connector and platform enabler.At the upcoming World Robot Conference 2025, Shoucheng is organizing an official sub-forum titled “Robotics Investment and Innovation Forum”, bringing together top-tier founders and venture capitalists to discuss commercialization strategies for humanoid robotics in the so-called “mass production year.” The forum serves as a bridge linking capital, technology, and market demand.In parallel, at the World Humanoid Robot Games, Shoucheng’s subsidiary Beijing Robotics Leasing Co. has provided 78 robots from its portfolio companies — including Booster Robotics, Galaxea-AI, Noetix Robotics, and Galbot — to support training in core competition categories such as football, athletics, and scene-based tasks. Several invested companies are also participating directly, enabling a full cycle of product testing, feedback, and application validation.Shoucheng’s ability to integrate investment, leasing, agency services, and operations has led to the creation of a scalable and repeatable robotics application infrastructure, positioning it as one of the few platform companies in the Hong Kong market with true industrial depth.3. A Rare Valuation Opportunity in Hong Kong’s Robotics MarketWhile many companies in China’s robotics ecosystem are either unlisted or trading at high valuations, Shoucheng Holdings currently trades at just around HK$1.90 and has completed multiple rounds of share buybacks. This signals strong management confidence in the company’s long-term value.In a market that favors “high growth + application-driven” assets, Shoucheng — with its triple focus on robotics, REITs, and medical technology — is emerging as one of the most compelling industrial platforms for investors riding the next robotics wave.Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月5日 - (亚太商讯 via SeaPRwire.com) - 8月4日，范式集团与海博思创签署合作协议，双方出资成立合资公司，业务覆盖"AI+储能"领域。这一合作标志着AI在能源存储的深度应用迈出关键一步，将为构建更智能、高效、安全的能源体系注入强大动力。在范式集团创始人戴文渊与海博思创创始人、董事长、首席执行官张剑辉的见证下，范式集团首席财务官刘楠与海博思创董事会秘书、首席财务官高书清代表双方公司签署合作协议，为双方未来的深度合作写下注解。范式集团联合创始人、首席研究科学家陈雨强与海博思创技术总裁杨洸等双方管理团队共同见证了这一重要时刻。AI赋能 范式集团驱动储能智慧升级作为核心技术引擎，范式集团将其在人工智能领域的前沿积累全面注入新公司：依托范式领先的AI Agent+世界模型能力，赋予储能系统前所未有的"智慧大脑"。电力市场AI解决方案能够实时预测电网供需两端的波动，结合储能自身的技术特点，动态优化储能场站的充放策略，提升效率的同时，达到经济收益最大化。与此同时，范式集团在能源行业的智能化应用已然拥有丰富的实践经验，相关技术也已经成功应用于负荷预测、电网优化、虚拟电厂等场景。此次合作将把其在能源领域特有的AI洞察力与海博思创的储能硬件深度融合，实现从"感知"到"决策"再到""执行"的闭环智能管理。坚实底座 海博思创铸就储能卓越基石依托储能系统研发、生产及全生命周期管理领域的技术实践，海博思创将成为合资公司的坚实后盾，提供其在储能系统全链条的顶尖能力：储能作为AI赋能能源革命的核心应用场景，具有重要的战略意义。海博思创以AI技术作为创新驱动力，依托研发、制造、运维、运营、交易等维度的海量数据基础，构建了基于AI算法的储能场景应用平台，实现了储能系统全生命周期的智能化运维管理，有力地推动了企业向综合能源服务商的转型升级。AI+储能 引领智慧能源革命范式集团与海博思创战略携手，绝非简单的技术叠加，而是通过深度协同，解决制约储能大规模发展的核心挑战：海博思创创始人、董事长、首席执行官张剑辉在签约仪式上表示："在全球能源格局重塑的当下，AI技术正成为推动能源变革的关键变量。海博思创与范式集团分别是储能与人工智能领域的领军者。两家公司的理念高度契合，通过此次合作，我们将实现储能技术与AI算法的深度融合，达到1+1>2的协同效应。"提及"AI+储能"，范式集团创始人戴文渊表示，新能源产业空间广阔，但天然波动性与系统复杂性正成为发展瓶颈。破解之道就在于双核驱动：储能构筑能源流转的物理基石，AI打造智能决策的数字中枢--前者稳定"波峰波谷"，后者优化"发-输-配-用"全链条效率。今天，范式集团与海博思创强强联合，将在"AI+储能"领域占有一席之地，创造出高于现有数十倍的产值。范式集团与海博思创的合作，将是储能产业走向数智化的关键一步。当顶尖AI大脑与强健储能躯干完美结合，制约储能大规模发展的种种挑战都被解决，"AI+储能"将释放其前所未有的潜力，共同推动全球能源转型进程。 Copyright 2025 亚太商讯 via SeaPRwire.com.

香港，2025年8月5日 - (亚太商讯 via SeaPRwire.com) - 8月4日，机器人产业ETF（159551）上涨2.44%，板块热度持续走高。人形机器人产业正步入从"技术爆点"向"场景兑现"的提速期。随着一系列行业事件密集催化，港股市场机器人板块进入新一轮结构性行情，其中最值得重点关注的标的之一，是已完成全链条布局的资产平台型公司--首程控股（0697.HK）。一、 行业催化不断，人形机器人从展台走向场地7月末举行的2025世界人工智能大会（WAIC）上，首次实现超150台人形机器人动态任务同台展示，覆盖工业、服务、医疗等多个场景，成为AIGC之后AI应用最具想象力的落地方向。与以往"静态展示"不同，本届展会首次呈现"任务级应用"，机器人在清扫、接待、搬运等场景中实现了类人化操控，标志着"硬件+算法+算力"协同模式加速成熟。与此同时，宇树科技开启IPO辅导、智元机器人筹备百台新品发布大会、世界机器人大会即将揭幕等密集消息叠加，正在持续强化板块情绪，并将产业链上的优质标的推向聚光灯下。而在港股市场，具有产业穿透力、已参与核心厂商实战、并掌握"投资+运营"落地能力的代表性公司仍属稀缺，首程控股正好填补这一空白。二、 从大会到应用，首程控股构建机器人产业的"场景通路"在一众仍停留于"资本故事"讲述阶段的公司中，首程控股的机器人战略已走入深水区，其角色正从投资方转向产业链接者与平台推动者。从行业桥梁层面来看，在即将举行的2025世界机器人大会中，首程控股主办了大会官方分论坛"机器人行业创投主题交流会"，聚焦"机器人量产元年"背景下的投资逻辑与场景落地策略。该论坛吸引了数十位头部机器人企业创始人和机构投资人，成为链接技术、资本与产业需求的重要平台。从场景落地层面来看，在同期举办的世界人形机器人运动会上，首程控股亦通过旗下北京机器人租赁公司，为赛事训练阶段提供了包括加速进化、星海图、松延动力在内的78台机器人设备，服务于足球、田径、场景赛等多个核心项目。多家被投企业还将亲自参赛，形成从技术验证到竞技检验的完整闭环。平台协同层面：依托"投资+租赁+代理+运营"的产业架构，首程控股已逐步形成一条覆盖研发、测试、交付、训练、反馈的机器人应用通路，成为港股市场中极少数具备真实产业穿透力的平台型公司。从主办分论坛、到实训设备支持、再到多家被投企业实战参赛，首程控股正在用一整套可复用、可扩展、可沉淀的数据与能力矩阵，持续拓宽机器人产业"从研发到场景"的落地通道。三、港股稀缺估值洼地，产业穿透力打开重估空间在当前国内机器人产业链上行周期中，大量公司仍处于估值高位或尚未上市阶段。而港股市场中，拥有实际运营能力、标的处于低估区间、产业兑现步入加速期的公司极为稀缺。目前首程控股股价仍处于1.9港元附近，已完成连续多轮股份回购，管理层用"真金白银"释放对公司中长期价值的高度认可。在港股资金偏好"高成长+场景逻辑"资产的背景下，具备"机器人+REITs+医疗科技"三重底层资产能力的首程控股，有望成为本轮机器人行情中最具穿透力的产业平台。Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 亚太商讯 via SeaPRwire.com.

PHILADELPHIA, PA, Aug 6, 2025 - (ACN Newswire via SeaPRwire.com) - TruMerit, a worldwide leader in international credentials evaluation to support health worker careers, today introduced the Certified Global Nurse (CGN), the world's first truly global credential for first-level, general nurses (RNs).TruMerit | Global careers. Care anywhere.The new, merit-based credential is available to any qualified nurse - from any country - to recognize their competencies, regardless of where they choose to live and work. It is awarded upon passage of TruMerit's Nurse Qualifying Exam (NQE), which applicants may take after verification of their nursing education and licensure.Previously known as the CGFNS Qualifying Exam and used by nurses migrating to the United States, the NQE was reinvented with a global focus to support the ongoing evolution of nursing practice worldwide and particularly the emergence of key challenges such as digital health, mental health, and climate change. This was achieved through a collaborative process involving more than 70 nursing experts from 50 countries, with all World Health Organization regions and World Bank country income levels represented. The experts agreed upon a core set of nursing practice standards after analyzing nursing competency frameworks from 37 countries.In addition to its role as a key requirement for the CGN credential, the upgraded exam continues to support other TruMerit programs - such as the VisaScreen® Visa Credentials Assessment Service and the Certification Program® - as a shared global framework for validating the applied knowledge and practice competence of nurses worldwide."The Certified Global Nurse credential offers nurses everywhere a common framework for meeting globally agreed-upon essential nursing practice standards," said Dr. Peter Preziosi, TruMerit's President and CEO. "When nurses carry the credential, their employers and colleagues will know that their applied nursing knowledge and skills are validated against a global benchmark, attesting to their qualifications for delivering quality healthcare."The credential is ultimately intended to provide nurses with greater mobility within the profession, within their native countries, and across geopolitical boundaries throughout their careers."By signifying work-readiness on an international scale, and thereby helping expand the pool of readily identifiable qualified nurses worldwide, global credentialing will become part of the solution to the challenges health systems are facing around the world," said Preziosi."We hope this credential can contribute to a sustained, collaborative effort involving many stakeholders-health ministries, international agencies, health systems, nursing schools, and nursing associations worldwide-to harmonize nursing education and practice and support the future growth of the global nursing workforce," he said.The Nurse Qualifying Exam is a proctored examination that will be offered four times a year at more than 1,000 Kryterion testing centers located around the world, with the first test window scheduled for November 10-14, 2025. Nurses who wish to earn a CGN credential and sit for the NQE in November must apply by September 30 at the TruMerit website, where they will find more information on the credential and how to prepare for the exam.The testing schedule for 2026 will be announced later this year.About TruMeritTruMerit is a worldwide leader in healthcare workforce development. Formerly known as CGFNS International, the organization has a nearly 50-year history supporting the career mobility of nurses and other healthcare workers - and those who license and hire them - by validating their education, skills, and experience as they seek authorization to practice in the United States and other countries. As TruMerit, this mission has been expanded to building workforce capacity that meets the needs of people in a rapidly evolving global health landscape. Through its Global Health Workforce Development Institute, the organization is advancing evidence-based research, thought leadership, and advocacy in support of healthcare workforce development solutions, including globally recognized practice standards and certifications that will enhance career pathways for healthcare workers. www.trumerit.orgContact InformationDavid St. Johndstjohn@trumerit.orgSOURCE: TruMerit Copyright 2025 ACN Newswire via SeaPRwire.com.